The World Health Organization's new list of essential medicines, those which should be available to everyone, anywhere, was issued today. To answer the rising concern about antimicrobial resistance, the antibiotics on the list have been divided in three groups, the last of which are to be used as a last resort. The list includes the first combination therapy to treat all six types of hepatitis C. However, no second line treatment for breast cancer has been added this year. Continue reading ->
Does glyphosate, better known under its brand name RoundUp, increase the risk of cancer in humans, or not? Yesterday, some World Health Organization members, while hailing a draft resolution on cancer later adopted, underlined a lack of coordination on glysophate between the WHO and its agency for cancer research. Separately, a renowned scientist sent a letter to European Commission President, Jean-Claude Juncker, saying the evaluations on the herbicide are flawed, and should be done again to safeguard public health. Continue reading ->
Speculation in the hallways of United Nations headquarters in Geneva was rampant in the days and hours leading up to this afternoon’s election of a new director general to lead the UN World Health Organization, but solid information about who will win was hard to come by. The outcome after a series votes is expected sometime tonight. Update! According to sources, the first round of voting is over. Results: Tedros 95, Nabarro 52, Nishtar 38. Second round update! Tedros 121, Nabarro 62. Third round underway. Continue reading ->
The World Health Organization has concluded a major one-day forum on fair pricing of medicines, bringing a wide range of stakeholders together in Amsterdam and coming up with several possible actions for the way ahead. Key points of discussion included a definition of fair pricing, moving away from value-based pricing, delinkage of price from research and development costs, and greater transparency, according to participants. Continue reading ->
The Medicines Patent Pool (MPP) has signed sublicense agreements with 11 manufacturers across multiple regions to expand access to generic baloxavir marboxil, a single-dose antiviral treatment for influenza that was originally developed by Swiss pharmaceutical company Roche.  The announcement, made the night before last Friday’s UN High-Level Meeting on Pandemic Prevention, Preparedness and Response, reignited […] Continue reading ->